Glenmark Launches Affordable Priced Ryaltris-Az Nasal Spray In India To Treat Allergic Rhinitis

Glenmark Launches Affordable Priced Ryaltris-Az Nasal Spray In India To Treat Allergic Rhinitis

By, Admin 4 May 2021

Glenmark Pharmaceuticals Limited, A Research-Led, Global Integrated Pharmaceutical Company, Announced The Launch Of Ryaltris-Az Nasal Spray For The Treatment Of Moderate To Severe Allergic Rhinitis, In India.Glenmark Being One Of The Leaders In Respiratory Segment, Has Been The First To Launch The Branded Generic Version At An Affordable Cost For The Treatment Of Allergic Rhinitis In India. This Will Provide Patients A Far More Convenient, Cost Effective Treatment Option In The Country.Glenmark Is The First Company In The World To Launch Ryaltris-Az, As A Novel Fixed Dose Combination Of Mometasone Furoate 50 Mcg + Azelastine 140 Mcg.According To A Study, Around 20-30 % Of The Indian Population Suffers From Allergic Rhinitis. Moreover, In India, Patients Have To Bear The Drug Cost On Their Own And So The Price Of The Drug Becomes A Major Factor That Impacts Treatment Adherence.While The Average Cost Of Therapy Of Top 10 Existing Brands Of The Similar Drug Category Is Rs. 365, Glenmark&Rsquo;S Ryaltris-Az Nasal Spray Has Been Launched At A Breakthrough Price Of Rs. 175/- Per Pack Of 75 Metered Doses (Md). This Cost Is Around 52% Less As Compared To The Average Price Of The Top 10 Brands Of The Similar Drug Category In The Market.Ryaltris-Az Nasal Spray, Developed By Glenmark, Is A Novel Fixed-Dose Combination Nasal Spray Of An Antihistamine And A Steroid, Indicated For Treatment Of Symptoms Associated With Allergic Rhinitis (Ar) In Patients Over 12 Years Of Age. It Relieves Symptoms Of Allergic Rhinitis, Including Stuffy Nose, Runny Nose, Nasal Itching, Sneezing, As Well As Itchy, Red And Watery Eyes.&Ldquo;Glenmark Has Been A Pioneer In Providing Access To The Latest Treatment Options For Respiratory Disease Patients In India. We Are Glad To Introduce Our Brand Ryaltris-Az, Which Is Clinically Studied And Cutting-Edge, At An Affordable Cost For Patients In The Country. Respiratory Segment Is A Key Area Of Focus For Glenmark And The Launch Of This Product Will Enable Us To Improve Access To Allergic Rhinitis Treatment By Providing An Effective, Convenient, World-Class And Affordable Treatment Option To Patients In India,&Rdquo; Said Alok Malik, Group Vice President &Amp; Business Head, India Formulations, Glenmark Pharmaceuticals.Allergic Rhinitis Is A Chronic Upper Respiratory Disease Estimated To Affect Around 10 To 40% Of The Population Worldwide. Indeed, Allergic Rhinitis Contributes To Missed Or Unproductive Time At Work, Sleep Problems And Decreased Involvement In Outdoor Activities. Being A Topical Therapy Ryaltris-Az Offers Many Advantages Over Oral Therapies, Such As Delivering Greater Concentrations Of Drug To The Receptor Sites At The Source Of The Allergic Inflammation And Reduced Risk Of Systemic Side Effects.Optimized And Quick Symptom Relief In Allergic Rhinitis Is Achieved With Combination Therapy Of An Intranasal Corticosteroid (Incs) And Intranasal Antihistamine (Inah) Nasal Spray, As Compared To Other Treatments. Renewed Aria (Allergic Rhinitis &Amp; Its Impact On Asthma) Guidelines Recommend Intranasal Corticosteroid &Amp; Intranasal Antihistamine As A 1St Line Of Treatment In Moderate To Severe Allergic Rhinitis. With Technological Advantage &Amp; Competitive Pricing With Ryaltris-Az, Glenmark Aims To Pass On This Benefit To Indian Patients Who Suffer From Moderate To Severe Allergic Rhinitis.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!